生殖期精神障碍的生物标志物研究综述
该叙述性综述通过PubMed检索2010年以来英文文献,聚焦围产期抑郁、焦虑与强迫症、产后精神病、经前期烦躁障碍及围绝经期抑郁六类疾病,汇总表观遗传、神经活性类固醇、免疫及神经影像领域的潜在生物标志物证据,结论是目前尚无任何生殖期精神障碍的临床可用生物标志物进入商业开发。
要点
- 表观遗传、神经活性类固醇、免疫与神经影像领域已有大量潜在生物标志物证据。
- 目前尚无任何生殖期精神障碍的临床可用生物标志物进入商业开发。
- 亟需纵向、大规模、多模态研究验证生物标志物在生殖各阶段的功能。
核心结论
- 生殖期精神障碍在表观遗传、神经活性类固醇、免疫功能和神经影像领域已有大量潜在生物标志物证据,但尚无临床可用标志物进入商业开发。
研究设计与样本
- 叙述性综述,通过PubMed检索2010年以来发表的英文文献,覆盖围产期抑郁、焦虑与强迫症、产后精神病、经前期烦躁障碍和围绝经期抑郁六类疾病,并附加生物标志物、表观遗传、神经活性类固醇、免疫、炎症和神经影像关键词。
主要发现
- 已发表证据涉及表观遗传、神经活性类固醇、免疫功能和神经影像四个领域的潜在生物标志物。
- 这些研究有潜力推进生物标志物开发、揭示疾病机制并改善诊疗策略。
- 目前尚无任何生殖期精神障碍的临床可用生物标志物处于商业开发中。
临床怎么用
- 临床暂不能依赖生物标志物诊断或治疗生殖期精神障碍,需继续依据临床评估。
- 关注表观遗传、神经活性类固醇、免疫和神经影像研究进展,为未来转化做准备。
局限性
- 为叙述性综述,检索限于2010年以来英文文献及指定关键词,可能遗漏其他语种或更早证据。
- 文中指出亟需纵向、大规模、多模态研究,反映现有证据在设计与规模上的不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While biomarkers are widely used in other medical fields, psychiatry has yet to introduce reliable biological diagnostic tools. Female reproductive transitions provide a unique window of opportunity for investigating psychiatric biomarkers. Hormonal changes across menstruation, pregnancy, parturition and perimenopause can have dramatic effects on mental health in vulnerable individuals, enabling the identification of unique biomarkers associated with these fluctuations. AIMS: This review integrates current evidence concerning potential biomarkers, with focus on recent human studies in perinatal depression, anxiety and obsessive-compulsive disorder, postpartum psychosis, premenstrual dysphoric disorder and perimenopausal depression. METHOD: We identified potential articles to be included in this narrative review by using PubMed to obtain articles in English since 2010 on the six conditions listed above, with the additional keywords of 'biomarker', 'epigenetics', 'neuroactive steroid', 'immune', 'inflammatory' and 'neuroimaging'. RESULTS: There is substantial published evidence regarding potential biomarkers of reproductive psychiatric disorders in the areas of epigenetics, neuroactive steroids, immune function and neuroimaging. This body of research holds significant potential to advance biomarker development, uncover disease mechanisms and improve diagnostic and therapeutic strategies, but there is as yet no clinically useful biomarker in commercial development for any reproductive psychiatric disorder. CONCLUSION: There is an urgent need for longitudinal, large-scale and multi-modal studies to examine potential biomarkers and better understand their functions across various stages of reproduction.
引用
- Etyemez S, Mehta K, Iyer S, et al. Biomarkers of reproductive psychiatric disorders. Br J Psychiatry. 2025. PMID: 40538358. doi:10.1192/bjp.2025.134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。